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Abstract
Objective The EPHESUS study demonstrated that
aldosterone blockade with eplerenone decreased mor-
tality in patients with left ventricular systolic dysfunc-
tion (LVSD) and heart failure after acute myocardial
infarction (AMI). The EPHESUS pharmacoeconomic
analysis was performed to evaluate the cost-effective-
ness of eplerenone in the Swiss setting.
Materials and methods A total of 6,632 patients with
LVSD and heart failure after AMI were randomized
to eplerenone or placebo and followed for a mean of
16 months. The co-primary endpoints were all-cause
death and the composite of cardiovascular death/
cardiovascular hospitalization. The evaluation of re-
source use included hospitalizations, outpatient ser-
vices, and medications. Survival beyond the trial
period was estimated using data from the Framingham
Heart Study, the Saskatchewan Health database, and
the Worcester Heart Attack Registry. The incremental
cost-effectiveness of eplerenone in cost per life-year
and quality-adjusted life-year gained was estimated.
The perspective of the Swiss third party payers was
used. Daily treatment costs of eplerenone were set at
CHF 3.88. All other resources were valued on the basis
of official tariffs. Discounting of the results was
performed at a rate of 3%.
Results The number of life-years gained with epler-
enone was 0.1083 based on Framingham, 0.0661 with
Saskatchewan and 0.1518 with Worcester survival
estimates. Total costs were CHF 1,028 higher over
the trial period in the eplerenone arm, due to drug
cost. The incremental cost-effectiveness ratio was CHF
10,145 per life-year gained with Framingham, CHF
16,178 with Saskatchewan, and CHF 7,693 with
Worcester survival estimates. The corresponding costs
per QALY were CHF 15,219, CHF 23,965 and CHF
11,337, respectively.
Conclusion Eplerenone is effective in reducing mor-
tality and, in Switzerland, is also cost-effective in in-
creasing years of life for patients with LVSD after
AMI.
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Introduction
Population studies, together with data derived from
medical records, reveal a range of estimated heart
failure (HF) prevalence of 1–10% [1]. In the general
European population, the prevalence of symptomatic
heart failure ranges from 0.4 to 2% [2]. The European
Society of Cardiology estimates that approximately 10
million patients suffer from heart failure in Europe [3].
Estimated incidence rates vary from approximately
0–1% per annum. Reasons for variation include age,
sex and, possibly, methodology. In community studies,
the 5-year mortality is between 50–60% while, in
patients requiring hospital admission, the annual
mortality is 10 –20% in those with mild–moderate
symptoms, and as high as 40–60% in severe HF. While
angiotensin-converting enzyme (ACE) inhibitor treat-
ment does significantly reduce mortality in all grades
of symptomatic HF, the annual mortality in severe
patients (i.e., New York Heart Association [NYHA]
Class IV) remains above 50% [4].
Evidence from studies based in the general popula-
tion, general practice and hospital strongly suggests an
emerging epidemic of HF in Europe [5]. Notably, a
further increase in the prevalence of the syndrome in
the elderly is expected in the next decades. The
majority of men and women with left ventricular
systolic dysfunction is asymptomatic. In people diag-
nosed with HF, sudden cardiac death occurs 6–9 times
the rate of the general population.
Several cost of illness and cost of care analyses sug-
gest that HF poses a great economic burden to health
care providers and society as a whole [8]. HF is the
single most frequent cause of hospitalization for people
aged 65 and older. In Switzerland the burden of heart
failure has been determined by Szucs et al [6]. Using
patient chart reviews, the annual costs was CHF 10,637
across all patients, CHF 3,951 in NYHA class I and II
patients, CHF 8,727 in class III patients and CHF 13,162
in class IV patients. These figures yielded a total expen-
diture of at least CHF 649 million annually. This cor-
responds to 1.6% of total Swiss health spending [6, 7].
The US Food and Drug Administration (FDA) has
approved the aldosterone receptor blocker eplerenone
for improving the survival of stable patients with left
ventricular systolic dysfunction (LVSD, i.e., ejection
fraction <40%) and clinical evidence of HF after acute
myocardial infarction (MI). More than one-third of MI
survivors develop HF, and when they do, their 5-year
mortality rate is 50%. FDA approval of the drug was
based on results of the EPHESUS (Eplerenone Post-
AMI Heart Failure Efficacy and Survival Study) trial.
Compared with post-MI HF patients on placebo and
standard therapy (ACE inhibitors and beta-blockers),
eplerenone on top of standard therapy, reduced mor-
tality significantly by 15%.
To use the existing resources optimally, the cost-
effectiveness of the different treatments must be taken
into consideration. If the same cost-effectiveness end-
points are used (e.g., costs per life-year saved), it is
possible to compare treatments across various indica-
tions. Although a US economic evaluation of the
EPHESUS trial has become available recently [8], it is
still required by national Swiss policy makers to obtain
cost-effectiveness estimates adapted to the particular
situation in Switzerland.
Study objective
The purpose of this study is to assess the cost-
effectiveness of eplerenone in patients with LVSD after
MI from the perspective of the Swiss healthcare system.
Materials and methods
Study design
A cost-effectiveness analysis was chosen for this study,
i.e., the numerator is expressed as incremental costs
and the denominator as incremental life-years. In
summary, we planned to calculate incremental costs
per life-year gained and incremental costs per quality-
adjusted life-year (QUALY) gained through treatment
with eplerenone in Switzerland. All costs are expressed
in Swiss francs (CHF).
The present analysis is retrospective and is based on
the results of the double-blind, randomised, controlled
clinical trial EPHESUS (Table 1) which was conducted
in Europe, Latin America, USA and Canada [9]. It was
assumed that the clinical findings of EPHESUS can be
transferred to Switzerland.
EPHESUS was designed to assess whether eplere-
none has a beneficial effect on morbidity and mortality
in patients with MI complicated by HF. A total of 6,642
patients with MI, left ventricular ejection fraction
(LVEF) </= 40%, and symptoms of HF, who were al-
ready on standard therapy, were randomly assigned to
25 or 50 mg of eplerenone, or placebo, once daily [2].
For standard therapy, 87% of patients were receiving
angiotensin-converting enzyme (ACE) inhibitors or
angiotensin-receptor blockers (ARBs), 75% were taking
beta-blockers, 88% were taking aspirin, and 60% were
taking diuretics. Patient characteristics at baseline were
similar between the eplerenone and placebo groups.
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During follow-up there were statistically significant
reductions in both primary endpoints, with 478 deaths
in the eplerenone group and 554 deaths in the placebo
group, a 15% reduction in total all-cause mortality
(RR 0.85, P = 0.008) and 13% fewer cardiovascular-
related deaths and cardiovascular hospitalizations (RR
0.87, P = 0.002) compared with the placebo group.
Resource information over the course of follow-up was
recorded prospectively on standardized form and
entered into a computerized database.
A brief comparison of the effects on clinical out-
comes of the EPHESUS study for the eplerenone and
placebo groups with respect to some particularly cost-
relevant clinical events is shown in Table 2. A detailed
description of study design and results has been
published previously [10].
Calculation of costs and effectiveness
General considerations
Treatment costs for patients in the eplerenone and
placebo arms of EPHESUS were calculated by multi-
plying study-wide resource utilization measures col-
lected in the trial by their corresponding local unit
costs, which were collected outside the trial. For this
study we universally apply Swiss unit costs to calculate
the incremental costs of eplerenone usage.
In EPHESUS resource utilization information was
collected on the following services: hospitalizations
(for any cause); emergency room (ER) visits; major
outpatient diagnostic procedures and tests; concomi-
tant medications; and eplerenone.
Table 1 Design of the EPHESUS study [20]
Objectives To establish whether the treatment with
eplerenone, an aldosterone blocker that
selectively blocks the mineralocorticoid
receptor reduces overall mortality or
hospitalization for cardiovascular events
among patients with acute myocardial
infarction complicated by left ventricular
dysfunction and heart failure who are
receiving optimal medical therapy.
Study design Multicentre, double blind, randomised,
placebo-controlled study in 674 centers and
37 countries in Europe, Latin America, the
United States and Canada.
Inclusion
criteria
Acute myocardial infarction
Left ventricular dysfunction with LVEF
<40%
Heart failure
Diabetics with LVEF <40% without
symptoms of heart failure
Exclusion
criteria
Use of potassium sparing diuretics
Serum creatinine >2.5 mg/dl
Serum potassium >5 mmol/l
Intervention Treatment initiation 3–14 days after a
myocardial infarction
Eplerenone 25 mg/d, titrated to 50 mg/d or
placebo
Endpoints Primary: time to death from any cause and
time to death from cardiovascular causes or
first hospitalization for a cardiovascular
event, including heart failure, recurrent
AMI, stroke, or ventricular arrhythmia.
Secondary: cardiovascular death or
cardiovascular hospitalisation
Period of
observation
Until 1,012 deaths occurred
Table 2 Comparison of treat-
ment effects in the
EPHESUS study [9]
Eplerenone
(n = 3,319)
Placebo
(n = 3,313)
P value
Baseline characteristics
Age (mean years) 64.2 T 11.3 64.7 T 11.7 0.14
Women (%) 28.3 29.6 0.26
Prior myocardial infarction (%) 27.4 26.8 0.52
Diabetes (%) 32.3 32.3 0.95
Hypertension (%) 59.7 61.2 0.22
History of heart failure (%) 14.2 15.2 0.24
Ejection fraction (mean percent) 33.1 T 6.0 33.0 T 6.1 0.55
Primary endpoints
Death (any cause) (%) 14.4 16.7 0.008
Death or hospitalization for cardiovascular events (%) 26.7 30.3 0.002
Secondary endpoints
Death from any cause or any hospitalization (%) 52.1 55.2 0.02
Death from cardiovascular causes (%) 12.3 14.6 0.005
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Resource utilization data were collected from all
patients enrolled in the trial from randomization the
end of the trial or death, whichever occurred first. Mean
resource utilization by service category and treatment
arm was calculated in the first, second and third years
following randomization on an intent-to-treat basis.
Hospitalizations
Two independent physicians who were blinded with
respect to therapy assigned one or more applicable
Diagnosis Related Group (DRG) codes to each hospi-
talization based on the reasons for admission. In cases
where multiple DRGs were recorded for a particular
hospitalization the DRG with the highest unit cost was
assigned to that hospitalization [11]. Imputation pro-
cedures were applied in order to address differences
between US and non-US countries of the clinical trial.
Trial-wide utilization rates are presented in Table 3.
Emergency room visits, diagnostic procedures and tests
Each recorded emergency room visit and outpatient
diagnostic procedure/test in EPHESUS was assigned to
a unique code by the two blinded physicians. On this
basis, a similar procedure as for the hospitalizations was
used to assign costs. Trial-wide utilization rates are
presented in the Table 4.
Eplerenone and concomitant medication
Concomitant medications used in the cost-effectiveness
analysis were limited to the 42 most commonly observed
in EPHESUS. There were 1,434 concomitant medica-
tions recorded by the EPHESUS investigators. Of these,
42 had at least 100,000 days of use or were the most com-
mon representative of their class of cardiac-related
medications (e.g., clonidine among alpha-blockers). These
42 medications represented approximately three-fourths
of the total concomitant medication days in the trial.
For eplerenone and each of these concomitant
medications, trial-wide mean utilization (days) in the
first, second and third years following randomization
was multiplied by its corresponding, country-specific
cost per day to arrive at total costs in each period. The
discounted present value of these over the three time
periods was then used in the ICER calculation.
Swiss unit costs
Swiss unit cost data for hospitalizations were derived by
utilizing the All Patient Diagnostic Related Groups
Table 3 Utilization rates for hospitalisation
DRG Trial-wide mean
utilization
Specific cerebrovascular disorders except
TIA
0.0243
Coronary bypass with PTCA 0.0025
Coronary bypass with cardiac
catheterization
0.0841
Percutaneous cardiovascular procedures 0.0418
Other permanent cardiac pacemaker
implant or PTCA coronary stenting
0.0137
Circulatory disorders with AMI without
major complications, alive
0.0703
Heart failure and shock 0.2260
Cardiac arrhythmias & conduction
disorders without complications
0.0397
Angina pectoris 0.1428
Table 4 Utilization rates for emergency room visits, procedures
and tests
Resource Trial-wide mean
utilization
Pacemaker, insertion or replacement of
pacemaker pulse generator only; single
chamber, atrial or ventricular
0.0068
Insertion or repositioning of electrode
lead(s) for single or dual chamber pacing
cardioverter-defibrillator and insertion of
pulse generator
0.0035
Myocardial perfusion imaging; (planar)
single study, at rest or stress (exercise or
pharmacologic), with or without
quantification
0.0882
Transcatheter placement of an
intracoronary stent(s), percutaneous,
with or without other therapeutic
intervention, any method; single vessel
0.0063
Percutaneous transluminal coronary
balloon angioplasty; single vessel
0.0069
Cardiovascular stress test using maximal or
submaximal treadmill or bicycle exercise,
continuous electrocardiographic
monitoring, and/or pharmacological stress;
tracing only without interpretation and
report
0.1599
Electrocardiographic monitoring for 24 h
by continuous original ECG waveform
recording and storage, and visual
superimposition scanning, recording.
0.0706
Right heart catheterization 0.0045
Left heart catheterization 0.1484
Electrophysiologic follow-up study with
pacing and recording to test effectiveness
of therapy, including induction or
attempted induction of arrhythmia
0.0097
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(AP-DRGs) [12], which are currently being implemented
throughout Switzerland. Costs for outpatient procedures
and tests were derived from the national tariff code
TARMED [13]. The resource use compositions of the
TARMED codes did not exactly correspond to those of
the codes assigned by the blinded physician reviewers,
that were reported in EPHESUS. Using the available
TARMED codes, approximations were therefore used in
many cases approximated to match the identified codes.
Current concomitant medications prices were calculated
on the basis of the Swiss Pharmaceutical Compendium
and of average daily recommended dosages [14]. Phar-
maceutical consumption in hospitals is included in the
AP-DRG costs for the corresponding procedure. Prices
are 2005 prices. All unit costs are displayed in Tables A1–
A3 in the Appendix.
Eplerenone unit cost
As the final prescription price of eplerenone was not
yet available at the time of this study, a most likely
estimate of CHF 3.88 per day (public price) was used
in the base case. A patient co-payment of 10% was
deducted from the pharmacy price, as this is manda-
tory for all outpatient medication prescriptions in
Switzerland. These total medication costs were pro-
jected assuming a patient compliance rate of 100%
throughout the treatment period.
Total costs
The resource utilization and unit cost information
described above was used to calculate the discounted
present value of treatment costs for all patients in the
eplerenone treatment arm and placebo arm of EPHE
SUS as follows: total costs by type of service for each
of the 3 years following randomization were calculated
by multiplying unit costs for each hospitalization, ER
visit, diagnostic procedures/test, concomitant medica-
tion and eplerenone by their corresponding mean
utilization values for the first, second and third year
following randomization. (By definition, eplerenone
utilization is zero for patients in the placebo arm of the
trial.) These costs were discounted by 3%. Discounted
costs were then summed over type of service (e.g.,
hospitalizations, ER visits, diagnostic procedures/tests,
concomitant medications and eplerenone), by treat-
ment arm (eplerenone or placebo).
Cost for HF hospitalizations, CV hospitalizations
(primary endpoint based) and all CV hospitalizations
were calculated from all hospitalizations where these
conditions were recorded as a DRG, whether or not
they were the most expensive DRG for that hospital-
ization. This method for computing costs is identical to
the method used to measure condition-specific utiliza-
tion in the published results of EPHESUS.
Effectiveness
Effectiveness was measured using two metrics: life
years gained; and QALYs. Life years gained was
defined as the expected number of years before death
at randomization (life expectancy) minus the observed
number of years before death following randomiza-
tion. Patients who did not die during the trial were
assumed to reach their life expectancy and, therefore,
had no life years lost. All life years lost estimates were
discounted using rates from 0 – 6%.
Life expectancy estimates were obtained from epi-
demiology studies conducted in different databases and
adjusted to specific Swiss life-expectancies. The ideal
data source from which to estimate lost life expectancy
would include longitudinal data, a large cohort of pa-
tients, patients with similar characteristics to those in
EPHESUS, and would be widely known and acknowl-
edged as credible. Because no single data source per-
fectly met all these criteria, the following three data
sources were used to estimate survival:
Framingham heart study
The estimated age and gender-specific life expectancy
for patients with congestive heart failure was published
from the Framingham Heart Study database [15, 16,
17]. The patient population for these estimates was
drawn from patients randomly enrolled in the original
study cohort between 1948 and 1951 with no cardio-
vascular disease upon enrollment.
It should be pointed out that the population used to
derive these life expectancy estimates differs from the
population in EPHESUS in two ways. First, life
expectancy is based on conditions in the 40 year
follow-up period after enrollment, which are unlikely
to be similar to conditions patients face currently.
Second, the Framingham analysis is based on patients
who have heart failure, whereas EPHESUS patients
had heart failure following MI.
Saskatchewan health
The Saskatchewan Health dataset contains adminis-
trative health care claims for residents of the province
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of Saskatchewan, Canada [18]. These data were used
to estimate a statistical model of life expectancy as a
function of the patient’s age, gender and history of
diabetes, MI, ischemic stroke, hypertension and HF.
Worcester heart attack study
The Worcester Heart Attack Study is an ongoing,
population-based study of myocardial infarction (MI)
[19, 20]. Patients are enrolled biannually from medical
centers in the Worcester, MA metropolitan area, since
1975. A total of 1,094 patients were selected from the
database on the basis of having a diagnosis of HF, an
ejection fraction of below 40% or unknown, and sur-
vived their initial hospitalization for MI. These data
were used to model life expectancy as a function of the
patient’s age, gender and history of diabetes, HF, hy-
pertension, and MI.
This population is not directly comparable to that of
EPHESUS because patients_ enrollment started in
1993. Consequently, the environment in which life
expectancy is estimated is different than what would
be expected for patients currently, although not to the
same extent as in the Framingham case. Further,
patients in this study are comparable to those enrolled
in EPHESUS because both groups had HF following
MI.
All three sources were used to estimate or model the
life expectancy of the EPHESUS patients according to
their baseline characteristics because no single source
perfectly met these criteria. For the Saskatchewan and
Worcester databases, data on 2,543 and 1,094 patients,
respectively, with heart failure after an AMI were ana-
lyzed with fractional polynomials and piecewise re-
gression to obtain death hazard functions over time
[21]. These functions were adjusted according to patient
characteristics through the use of separate Cox pro-
portional-hazards models derived from the same data.
For patients who died during the trial, life-years lost
were obtained by subtracting the in-trial survival times
from estimated age- and sex-specific life expectancy
estimates [22]. Patients were considered to have 0 life-
years lost if they survived during the trial period.
Average life-years lost for each treatment group were
calculated across all patients who died and survived in
each arm of the trial. The difference in average life-
years lost because of deaths (placebo minus eplere-
none) yields an estimate of the life-years gained with
eplerenone.
Based on these estimates, life years lost estimates
were calculated as presented in the table below for
discount rates varying from 0 to 6%.
Quality adjusted life years (QALYs)
Conceptually, life years gained with low quality of life
are less valuable than life years gained with high
quality of life. Survival was adjusted for quality of life
by multiplying each patient’s life years lost by their
utility index constructed from the EQ-5D [23] quality
of life instrument. The EQ-5D was administered to a
subset of patients (N = 2,280) in 10 of the 37 countries
included in EPHESUS. Of these 2,280 patients, the
average response rate across all eight administrations
of the EQ-5D (i.e., baseline and months 1, 3, 6, 12, 18,
24, and 30) was 53% for patients in the eplerenone
group and 54% for patients in the placebo group.
Patients with missing values had their score values
imputed using the average score for patients in the
same treatment arm with the same follow-up time.
Patients who survived the trial had zero QALYs
lost. For patients who died during the trial, QALYs
lost were calculated by multiplying that patient’s life
years lost by the average utility among surviving trial
participants in the same treatment arm. For example,
if a patient in the eplerenone arm died in month 7, her
life years lost would be multiplied by the average
utility of all patients in the eplerenone arm measured
at month 6. Indirect costs (e.g., costs related to loss of
work) and intangible costs (e.g., pain) were not in-
cluded in this calculation.
Sensitivity analyses
Sensitivity analyses were performed to test the vari-
ability of results (i.e., the costs per life-year saved). For
simplicity only the medication costs for eplerenone
were varied by T 20%. We judge these to be the most
important, costly parameters. In addition, the discount
rate was increased from 3 to 6%.
Results
Table 5 shows the individual costs. These were CHF
16,970 in the group treated with eplerenone and CHF
15,941 in the placebo group. It is evident that there is
an additional medication cost of approximately CHF
1,468 per patient over 16 months in the eplerenone
group compared to the placebo group in terms of eple-
renone costs. In contrast, a savings potential can be seen
in the eplerenone group, as the costs of hospitalisations
and outpatient procedures were lower. Thus, the total
cost difference between the two groups is CHF 1,028.
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The number of life-years gained with eplerenone
treatment was 0.1083 based on Framingham, 0.0661
with Saskatchewan and 0.1518 with Worcester survival
estimates. The corresponding incremental gains in
QALYs were 0.0722, 0.0446 and 0.1029. (Table 6)
The incremental cost-effectiveness ratio of eplere-
none compared with placebo was CHF 10,145 per life-
year gained in the analysis using Framingham data.
When the Sakskatchewan estimates were used, the
ICER was CHF 16,178 per life-year gained. Finally the
Worcester-based analysis yielded a result of CHF 7,693
per life-year gained. All these estimates are well below
the commonly accepted threshold of CHF 50,000 per
life-year gained for healthcare interventions in Swit-
zerland, which are covered by third party payers. The
corresponding incremental costs per QALY gained
were CHF 15,219, CHF 23,965 and CHF 11,337 for the
Framingham-, Saskatchewan- and Worcester-based
analyses (Fig. 1).
The results of the sensitivity analysis confirm that
the estimated range of incremental cost-effectiveness
ratios were between 7,688 and CHF 20,796 per life-
year gained and between CHF 8,101 and CHF 30,804
per QALY. Table 7 displays the cost-effectiveness of
selected health care interventions.
Discussion
The present economic assessment of eplerenone has
proved that the administration of this medication is a
highly economically viable option in patients with
LVSD after acute myocardial infarctions. The benefits
of eplerenone are attributed almost exclusively to the
reduction of related hospitalisations. However, the
economic performance of a medical intervention can
never be judged in isolation, but must always be seen
in comparison to other interventions and should be
discussed in relation to this background. The position-
ing of the results in the context of the cost-effective-
ness of other interventions is shown in Table 8 and
makes it clear that treatment with eplerenone is in a
more favourable range, than can be attained by some
other broadly accepted interventions.
Our results are similar to those of the cost-effective-
ness study, which has been conducted by the original
EPHESUS investigators [8]. The number of life-years
gained with eplerenone was 0.1014 based on Framing-
ham (95% CI, 0.0306 to 0.1740), 0.0636 with Saskatch-
ewan (95% CI, 0.0229 to 0.1038), and 0.1337 with
Worcester (95% CI, 0.0438 to 0.2252) data. Cost was
1,391 dollars higher over the trial period in the
eplerenone arm (95% CI, 656 to 2,165) because of drug
cost. The incremental cost-effectiveness ratio was
13,718 dollars per life-year gained with Framingham
(96.7% under 50,000 dollars per life-year gained),
21,876 dollars with Saskatchewan, and 10,402 dollars
with Worcester.
Table 6 Expected additional life expectancy due to eplerenone
therapy
Eplerenone
life years
lost
Placebo life
years lost
Gain in life
years with
Eplerenone
Life expectancy
Framingham j0.57592991 j0.68421821 0.1083
Saskatchewan j0.32162958 j0.38771208 0.0661
Worcester j0.69649316 j0.84833168 0.1518
Quality adjusted life expectancy
Framingham j0.42124600 j0.49341921 0.0722
Saskatchewan j0.23362852 j0.27826339 0.0446
Worcester j0.50919828 j0.61213055 0.1029
Table 5 Costs in the eplerenone and placebo groups over
1.3 years (16 months) in Swiss Francs
Resource used Eplerenone Placebo Eplerenone–
Placebo
Hospitalizations 12,060.17 12,517.25 (457.09)
HF hospitalizations 2,116.53 2,746.99 (630.46)
CV hospitalizations
(primary
endpoint-based)
3,451.18 4,020.28 (569.10)
All CV
hospitalizations
10,920.14 11,380.00 (459.86)
Outpatient
procedures
391.87 367.89 23.98
Concomitant
medications
3,022.94 3,026.36 (3.43)
Emergency room
visits
27.04 29.78 (2.74)
Eplerenone 1,467.76 – 1,467.76
Total 16,969.78 5,941.29 1,028.49
Fig. 1 Overview of cost-effectiveness results.
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A limitation of the present analysis is certainly that
the results of the EPHESUS study, which was con-
ducted in several countries across Europe, Latin
America, the United States and Canada, were trans-
ferred to the Swiss healthcare setting. Hence, we had to
adjust our calculations, including the estimated life
expectancy of patients in Switzerland in order to
determine cost-effectiveness. EQ-5D was also only
administered to a subgroup of patients in EPHESUS,
which gives potential for biases in the QALYs. There
Table 7 Univariate sensitivity analysis: Effect of variation of key input variables on cost-effectiveness ratios (YOLS and QALY)1
Variable Base
value
Cost-
effectiveness
Framingham Saskatchewan Worcester
Lower
estimatea
Upper
estimatea
Lower
estimatea
Upper estimatea Lower
estimatea
Upper
estimatea
Eplerenone costs 1,468 CHF/YOLS 7,250 13,041 11,560 20,796 5,497 9,888
CHF/QALY 10,875 19,563 17,125 30,804 8,101 14,573
Hospitalization costs (457) CHF/YOLS 11,047 9,244 17,616 14,740 8,376 7,009
CHF/QALY 16,572 13,866 26,095 21,834 12,345 10,330
Outpatient
procedure costs
19 CHF/YOLS 10,098 10,193 16,103 16,253 7,657 7,729
CHF/QALY 15,148 15,290 23,853 24,076 11,284 11,390
Concomitant
medications costs
(3.43) CHF/YOLS 10,152 10,139 16,189 16,167 7,698 7,688
CHF/QALY 15,299 15,209 23,980 23,949 11,345 11,330
Emergency room
visits costs
(2.74) CHF/YOLS 10,151 10,140 16,187 16,170 7,697 7,689
CHF/QALY 15,227 14,211 23,977 23,952 11,343 11,331
Discount rateb 3% CHF/YOLS 9,498 10,801 15,564 16,782 6,774 8,639
CHF/QALY 14,250 16,200 23,042 24,972 9,992 12,729
a Lower estimate: j20%, upper estimate: +20%
b Lower estimate: 0%, upper estimate: 6%
1 All prices adjusted to 2005
Table 8 Cost-effectiveness of selected cardiovascular interventions in Switzerland
Intervention Cost per life-year saved
in Swiss Francs
Source
Lisinopril in congestive heart failure (ATLAS) <0* Ess and Szucs [25]
Captopril after myocardial infarction (SAVE) 1,600 Szucs et al. [26]
Atorvatstatin in patients with ACS 3,075 Szucs and Meier [27]
Beta-blockers for post-myocardial infarction patients at high risk 3,600 Goldman et al. [28]
Pravastatin therapy for CHD patients with slightly increased
cholesterol values (LIPID)
6,985 Szucs et al. [29]
Eplerenone in patients with leftventricular dysfunction
after AMI (EPHESUS)
10,145 Present study
Pravastatin therapy for CHD patients with increased
cholesterol values (PLAC I/II)
12,800 Berger K, Klose G, Szucs TD [37]
Low cholesterol diet for men aged Q60 years with a cholesterol
value of 180 mg/dl (4.7 mmol/l)
14,480 Taylor et al. [30]
Amlodipine therapy for CHD patients with normal cholesterol
(PREVENT)
14,650 Cathomas et al. [31]
Perindopril in patients with CHD (EUROPA) 17,131 Szucs and Darioli [32]
Pravastatin therapy for CHD patients over 60 years with normal
cholesterol values (CARE)
18,400 Berger K, Klose G, Szucs TD [37]
Antihypertensive agents for patients aged Q40 years with
diastolic blood pressure levels Q105 mm Hg
19,280 Stason and Weinstein [33]
Beta-blockers for post-myocardial patients at low risk 20,400 Goldman et al. [28]
Hypertensive patients with multiple risk factors (ASCOT) 20,003 Szucs et al. [34]
Clopidogrel in coronary secondary prevention (CAPRIE) 24,705 Haldemann et al. [35]
tPA for myocardial infarction (GUSTO IV) 39,440 Mark et al. [36]
* Values < 0 denotes net savings, i.e., a dominant economic strategy
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are indications that the influence of other risk factors
may possibly vary in the degree of severity to which
they affect the Swiss population compared with the
original study population. However, the patient popu-
lation of the EPHESUS study is comparable to a Swiss
AMI population with respect to age, co-morbidity and
concomitant medication [24]. It should also be pointed
out that patients in the EPHESUS study are only partly
representative of the total collective of corresponding
patients in Switzerland. We also consider life expec-
tancies between Europe and North America to be sim-
ilar. Unfortunately no life expectancy is provided by
Framingham database for individuals with CHF youn-
ger than 60. In EPHESUS, if a patient died before 60,
the life expectancy for age 60~70 was used. As always,
study patients are naturally carefully selected in terms
of co-morbidity, compliance and quality of care. In this
respect, the results of the EPHESUS study correspond
to the best-case scenario.
Another limitation may be the issue of extrapolating
costs beyond the scope of the clinical trial. In the
EPHESUS US economic analysis, costs were estimat-
ed beyond the trial period based on projections of
costs within the trial period and life expectancy. This
would be technically very difficult in Switzerland. In the
US, when costs were extrapolated beyond the trial
period, the ICER went up by about 50%. Similar results
may be expected in Switzerland, but it is uncertain.
Additionally, in EPHESUS, the EQ-5D was only ad-
ministered to 2,280 patients from 10 of the 35 enrolling
countries. We realized that this is a limitation, and used
cost per QALYs gained as sensitivity analysis.
Economic evaluations are of practical relevance for
the general practitioner to the extent that the conscious
use of economical medical therapies reduces their fear
and uncertainty about budget adherence and recourse,
and justifies his prescribing practice. In particular in the
field of cardiovascular interventions there is a need for
clinical and economical rationing due to the increased
availability of treatment options. The use of cost-ef-
fective medical therapies offers the individual doctor
some relief for their medication budget, e.g., by reduc-
ing the prescriptions of concomitant medications, and a
greater individual manoeuvrability within the frame-
work of the fixed prescription budget allocated to them.
In addition, economic evaluation can be used as an
explicit tool to ensure Bvalue for money’’ where scare
resources have become a constant threat to the overall
health care expenditures.
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Table A1 Unit costs outpatient procedures
Description Local unit
cost
Pacemaker, insertion or replacement
of pacemaker pulse generator only;
single chamber, atrial or ventricular
1,094.23
Insertion or repositioning of electrode
lead(s) for single or dual chamber
pacing cardioverter-defibrillator
and insertion of pulse generator
1,024.72
Myocardial perfusion imaging; (planar)
single study, at rest or stress (exercise
or pharmacologic), with or without
quantification
141.98
Transcatheter placement of an intracoronary
stent(s), percutaneous, with or without
other therapeutic intervention, any
method; single vessel
1,526.13
Percutaneous transluminal coronary
balloon angioplasty; single vessel
2,289.20
Cardiovascular stress test using maximal
or submaximal treadmill or bicycle
exercise, continuous electrocardiographic
monitoring, and/or pharmacological stress;
tracing only without interpretation
and report
385.29
Electrocardiographic monitoring for 24 h
by continuous original ECG waveform
recording and storage, and visual
superimposition scanning, recording.
172.69
Right heart catheterization 561.25
Left heart catheterization 995.89
Electrophysiologic follow-up study
with pacing and recording to test
effectiveness of therapy, including
induction or attempted induction
of arrhythmia
1,067.65
Upper gastrointestinal endoscopy,
simple primary examination
(e.g., with small diameter flexible
endoscope) separate procedure
341.69
Computed tomography, head and brain;
without contrast material
108.40
Magnetic resonance (e.g., proton)
imaging, orbit, face, and neck;
without contrast material(s)
209.33
Magnetic resonance (e.g., proton) imaging,
brain (including brain stem);
without contrast material(s)
226.27
Radiologic examination, chest;
single view, frontal
39.21
Computed tomography, thorax;
without contrast material
136.31
Magnetic resonance (e.g., proton) imaging,
any joint of lower extremity;
without contrast material
245.44
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Computed tomography, abdomen;
without contrast material
136.31
Magnetic resonance (e.g., proton) imaging,
abdomen; without contrast material
204.83
Cardiac magnetic resonance imaging
for morphology; without contrast material
263.93
Ultrasound, abdominal, B-Scan and/or
real time with image documentation;
complete
112.52
Electrocardiogram, routine ECG with
at least 12 leads; tracing only
without interpretation or report
32.32
Transthoracic echocardiography for
congenital cardiac anomalies; complete
131.28
Echocardiography, transthoracic, real time
with image documentation (2D),
with or without M-mode recording
during rest and cardiovascular stress test
368.24
Table A1 (continued)
Description Local unit cost
Table A2 (continued)
Table A2 Unit cost: hospitalisation
Description Local unit cost
Specific cerebrovascular disorders
except TIA
14,705.48
Coronary bypass with PTCA 50,000.00
Coronary bypass W cardiac CATH 44,476.76
Percutaneous cardiovascular
procedures
10,000.00
Other PERM cardiac pacemaker
implant or PTCA W coronary
ART stent
12,231.73
Circulatory disorders W AMI W/O
major COMP DISCH alive
12,760.27
Heart failure & shock 14,810.10
Cardiac arrhythmias & conduction
disorders W/O CC
3,084.27
Angina pectoris 5,731.73
Other infectious & parasitic diseases
diagnoses
8,499.66
Other disorders of nervous system
w/o cc
3,356.40
Chronic obstructive pulmonary disease 14,935.20
Simple pneumonia & pleurisy age >17
w/o cc
9,047.86
Other respiratory system diagnoses
w/o cc
3,269.42
Heart transplant 80,000.00
Cardiac valve & oth major cardiothoracic
proc w/o card cath
56,499.86
Prm card pacem impl w ami/hr/shock
or aicd lead or gnrtr
56,499.86
Other circulatory system o.r. procedures 27,473.15
Cardiac arrest, unexplained 5,302.68
Peripheral vascular disorders
w/o cc
8,466.42
Hypertension 6,487.61
Syncope & collapse w/o cc 3,000.86
Chest pain 2,277.39
Other circulatory system diagnoses
w/o cc
4,156.36
Esophagitis, gastroent & misc digest
disorders age >17 w/o cc
3,050.19
Other musculoskelet sys & conn tiss
o.r. proc w/o cc
8,029.15
Diabetes age >35 13,378.89
Renal failure 14,225.32
Other kidney & urinary tract diagnoses
age >17 w/o cc
1,951.41
Red blood cell disorders age >17 8,340.36
Reticuloendothelial & immunity disorders
w/o cc
4,374.16
Traumatic injury age >17 w/o cc 6,079.53
Allergic reactions age >17 2,259.40
Complications of treatment w/o cc 3,091.89
cc: complications
Table A3 Unit cost: medication
Drug name Local cost per day (CHF)
Abciximab in male 1,686.71
Abciximab in female 1,472.04
Acetaminophen 0.72
Allopurinol 4.15
Amiodarone 0.76
Amlodipine 1.47
Aspirin 0.19
Atenolol 4.23
Atorvastatin 2.24
Bisoprolol 4.56
Captopril 4.61
Carvedilol 0.80
Clonidine 2.00
Clopidogrel 3.26
Digoxin 0.10
Enalapril 0.94
Fenofibrate 0.95
Fosinopril 1.44
Furosemide 0.33
Glyburide
Hydrochlorothiazide 0.35
Ibuprofen 0.57
Insulin 4.86
Isosorbide Dinitrate 0.51
Isosorbide Mononitrate 0.84
Levothyroxine 0.16
Lisinopril 0.56
Losartan 1.58
Magnesium 0.40
Metformin 0.29
Metoprolol 0.65
Molsidomine 0.57
Nitroglycerin 1.78
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